NO20031274L - Anvendelse av immidazokinolinaminer som adjuvanter i DNA- vaksinasjon - Google Patents

Anvendelse av immidazokinolinaminer som adjuvanter i DNA- vaksinasjon

Info

Publication number
NO20031274L
NO20031274L NO20031274A NO20031274A NO20031274L NO 20031274 L NO20031274 L NO 20031274L NO 20031274 A NO20031274 A NO 20031274A NO 20031274 A NO20031274 A NO 20031274A NO 20031274 L NO20031274 L NO 20031274L
Authority
NO
Norway
Prior art keywords
immidazoquinolinamines
adjuvants
dna vaccination
vaccination
dna
Prior art date
Application number
NO20031274A
Other languages
English (en)
Other versions
NO20031274D0 (no
Inventor
Lindy Louise Thomsen
John Philip Tite
Peter Topley
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9899764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20031274(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20031274D0 publication Critical patent/NO20031274D0/no
Publication of NO20031274L publication Critical patent/NO20031274L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20031274A 2000-09-20 2003-03-19 Anvendelse av immidazokinolinaminer som adjuvanter i DNA- vaksinasjon NO20031274L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0023008.6A GB0023008D0 (en) 2000-09-20 2000-09-20 Improvements in vaccination
PCT/GB2001/004207 WO2002024225A1 (en) 2000-09-20 2001-09-20 Use of immidazoquinolinamines as adjuvants in dna vaccination

Publications (2)

Publication Number Publication Date
NO20031274D0 NO20031274D0 (no) 2003-03-19
NO20031274L true NO20031274L (no) 2003-05-19

Family

ID=9899764

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031274A NO20031274L (no) 2000-09-20 2003-03-19 Anvendelse av immidazokinolinaminer som adjuvanter i DNA- vaksinasjon

Country Status (24)

Country Link
US (3) US20040076633A1 (no)
EP (1) EP1318835B1 (no)
JP (1) JP2004509150A (no)
KR (1) KR100876263B1 (no)
CN (1) CN1197620C (no)
AR (1) AR035586A1 (no)
AT (1) ATE401097T1 (no)
AU (2) AU8790801A (no)
BR (1) BR0113982A (no)
CA (1) CA2422863A1 (no)
CZ (1) CZ2003792A3 (no)
DE (1) DE60134866D1 (no)
ES (1) ES2309086T3 (no)
GB (1) GB0023008D0 (no)
HU (1) HUP0301180A3 (no)
IL (1) IL154947A0 (no)
MX (1) MXPA03002453A (no)
MY (1) MY138978A (no)
NO (1) NO20031274L (no)
NZ (1) NZ524792A (no)
PL (1) PL360895A1 (no)
TW (1) TWI287453B (no)
WO (1) WO2002024225A1 (no)
ZA (1) ZA200302231B (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
GB0206461D0 (en) * 2002-03-19 2002-05-01 Glaxo Group Ltd Improvements in vaccination
DK1487485T3 (da) * 2002-03-19 2011-03-14 Powderject Res Ltd Imidazoquinolinadjuvanser til DNA-vacciner
CA2484044A1 (en) * 2002-03-19 2003-10-02 Powdermed Limited Imidazoquinolineamines as adjuvants in hiv dna vaccination
DK1545597T3 (da) * 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
CA2510375A1 (en) 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
BRPI0413558A (pt) * 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
JP2007504145A (ja) * 2003-08-25 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 免疫刺激性の組み合わせおよび治療
US8961477B2 (en) * 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
AU2004268625B2 (en) 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
AU2004270201A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
CA2545825A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
JP2007517035A (ja) * 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
EP1699788A2 (en) * 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
WO2005094531A2 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) * 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) * 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US20070259881A1 (en) * 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
WO2006065280A2 (en) * 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
EP1804583A4 (en) * 2004-10-08 2009-05-20 3M Innovative Properties Co ADJUVANT FOR DNA VACCINE
DE102004049223A1 (de) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
EP1819364A4 (en) * 2004-12-08 2010-12-29 3M Innovative Properties Co COMPOSITIONS, IMMUNOMODULATORY COMBINATIONS AND ASSOCIATED METHODS
PL1830876T3 (pl) * 2004-12-30 2015-09-30 Meda Ab Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi
JP5543068B2 (ja) * 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
EP1831221B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Substituted chiral fused 1,2 imidazo 4,5-c ring compounds
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
EA200800782A1 (ru) * 2005-09-09 2008-08-29 Коли Фармасьютикал Груп, Инк. ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ
KR20080083270A (ko) 2005-11-04 2008-09-17 콜레이 파마시티컬 그룹, 인코포레이티드 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
US8088788B2 (en) 2006-03-15 2012-01-03 3M Innovative Properties Company Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
US8329721B2 (en) * 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
CA2645832A1 (en) * 2006-04-25 2007-11-01 Intercell Ag Hcv vaccinations
US20090060928A1 (en) * 2006-05-26 2009-03-05 Jean-Claude Bystryn Topical Toll Like Receptor Ligands as Vaccine Adjuvants
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
MX2008016036A (es) * 2006-06-20 2009-04-07 Transgene Sa Vacuna viral recombinante.
ES2444695T3 (es) 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
US7906506B2 (en) * 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
CN100450484C (zh) * 2006-10-11 2009-01-14 北京科信必成医药科技发展有限公司 一种咪喹莫特混悬溶液及其凝胶剂
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
CN103736086A (zh) * 2007-02-15 2014-04-23 曼康公司 用于增强t细胞应答的方法
US8709445B2 (en) 2007-07-31 2014-04-29 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2508190B1 (en) * 2009-12-03 2021-06-02 Aureo Co., Ltd. Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages
CN101850117B (zh) * 2010-06-03 2012-05-30 国家兽用生物制品工程技术研究中心 一种复方免疫佐剂及疫苗
US9242980B2 (en) 2010-08-17 2016-01-26 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
SI3173427T1 (sl) 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
BR112013031039B1 (pt) 2011-06-03 2020-04-28 3M Innovative Properties Co compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
GB201310578D0 (en) 2013-06-13 2013-07-31 Univ Nottingham Trent Electroactive actuators
WO2015023649A2 (en) 2013-08-12 2015-02-19 3M Innovative Properties Company Peptides for enhancing transdermal delivery
JP7145757B2 (ja) 2015-10-12 2022-10-03 リフロー メディカル インコーポレイテッド 突出する薬剤送達フィーチャーを有するステント、ならびに、関連のシステムおよび方法
US10533007B2 (en) 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
KR20180134395A (ko) 2016-04-19 2018-12-18 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
WO2018217897A1 (en) * 2017-05-23 2018-11-29 David Weiner Compositions and method for inducing an immune response
US11524069B2 (en) 2017-09-13 2022-12-13 Sanofi Pasteur Human cytomegalovirus immunogenic composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
KR100564268B1 (ko) * 1996-10-23 2006-03-27 와이어쓰 백신
GB9818627D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination

Also Published As

Publication number Publication date
GB0023008D0 (en) 2000-11-01
ZA200302231B (en) 2004-05-05
US20070248614A1 (en) 2007-10-25
NO20031274D0 (no) 2003-03-19
EP1318835A1 (en) 2003-06-18
HK1057700A1 (en) 2004-04-16
IL154947A0 (en) 2003-10-31
WO2002024225A1 (en) 2002-03-28
BR0113982A (pt) 2003-08-19
MY138978A (en) 2009-08-28
ES2309086T3 (es) 2008-12-16
DE60134866D1 (de) 2008-08-28
CN1473051A (zh) 2004-02-04
AU2001287908B2 (en) 2005-06-30
EP1318835B1 (en) 2008-07-16
MXPA03002453A (es) 2003-06-19
US20110002953A1 (en) 2011-01-06
JP2004509150A (ja) 2004-03-25
KR20040023566A (ko) 2004-03-18
CZ2003792A3 (cs) 2004-12-15
CN1197620C (zh) 2005-04-20
NZ524792A (en) 2004-09-24
KR100876263B1 (ko) 2008-12-26
AR035586A1 (es) 2004-06-16
TWI287453B (en) 2007-10-01
PL360895A1 (en) 2004-09-20
AU8790801A (en) 2002-04-02
US20040076633A1 (en) 2004-04-22
ATE401097T1 (de) 2008-08-15
HUP0301180A2 (hu) 2004-03-01
CA2422863A1 (en) 2002-03-28
HUP0301180A3 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
NO20031274D0 (no) Anvendelse av immidazokinolinaminer som adjuvanser i DNA- vaksinasjon
DK1296715T3 (da) Multivalent vaccinesammensætning
NO20031483L (no) Vaksine
DK1946771T3 (da) Multivalent vaccinesammensætning
NO20024172L (no) Vaksine
DK1023904T3 (da) Adjuvanser til anvendelse i vacciner
PL363005A1 (pl) Szczepionki
NO20025357D0 (no) Antranylamider og deres anvendelse som legemidler
DE60038166D1 (de) Impfstoff gegen bakterielle antigene
DK1150712T3 (da) Vaccineformuleringer mod human papillomavirus
EP1385538A4 (en) CHIMERIC VACCINE
DE60027029D1 (de) Kombinierte impfstoffzusammensetzungen
DK1427444T3 (da) West-nil-vaccine
EP1423141A4 (en) VACCINE
DZ3219A1 (fr) Vaccin
NO20033882D0 (no) Vaksine
EP1549135A4 (en) VACCINE COMPOSITIONS AND AUXILIARY
EP1450752A4 (en) MULTIVALENT VACCINE COMPOSITIONS CONTAINING STREPTOCOCCUS AND METHODS OF USE
EP1409011A4 (en) PRIME-BOOST IMPF STRATEGY (28.07.01)
DE60142051D1 (de) Herstellung von perfluorolefinen
IS6381A (is) Nýjung við notkun mótefna í bóluefni
ATE439855T1 (de) Transformierender wachstumsfaktor alpha enthaltende impfstoffzusammensetzung
NO20055515D0 (no) 7-azaindoler og deres anvendelse som terapeutiske midler
NO20023517D0 (no) Stol
NO20003763D0 (no) Regulerbar stol